Abstract: A piping system for housing system components for regulating the flow of fluid therethrough is provided. The piping system includes an inner small diameter length of piping through which hot fluids flow, an outer larger diameter length of piping surrounded by cold fluid, and an annulus between the small and larger diameter piping in which the system components are received. Insulation material extends about a predetermined section of the small diameter length of piping for restricting heat transfer therefrom to the system components in the annulus and allowing heat transfer from the system components in the annulus to the outer piping.

Abstract: An apparatus includes an engagement device to be disposed on a landing string. The engagement device includes a retracted state to allow the apparatus to be run inside a riser and an expanded state to engage the riser to secure the apparatus to the riser. The apparatus further includes an actuator assembly to be disposed on the landing string. The actuator assembly is remotely actuatable from a sea surface to rotate a tubing of the landing string relative to the engagement device to rotate the landing string to orient a tubing hanger assembly.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

Abstract: A technique enables protection of subsea wells. The technique employs a subsea test tree designed to ensure control over the well in a variety of situations. The subsea test tree is formed with at least one shut-off valve to protect against unwanted release of fluids from the subsea test tree. The subsea test tree also is coupled with and controlled by a control system having a subsea control module mounted to an interior mandrel.

Abstract: A technique facilitates powering of devices at a subsea location without requiring routing of hydraulic pressure and/or electric signals through an umbilical from a surface location. A fluid flow, such as an injection chemical fluid flow, is at least partially routed through a flow converter disposed at a subsea location. The flow converter converts energy from the fluid flow to energy used to operate a power generation device. The power generation device may be designed to generate electrical, hydraulic, or other suitable power which is utilized at the subsea location.

Abstract: A control system is for completion installation, intervention and testing activities at a subsea location. The control system has a first control circuit at a surface location; a subsea test tree located in a blowout preventer at the subsea location, the second control circuit located within a riser extending from the blowout preventer towards the surface location; and a plurality of sensors monitoring characteristics of the subsea location. The second control circuit communicates with the first control circuit and receives the characteristics of the subsea location. The second control circuit also controls electrically powered subsea valves based upon commands from the first control circuit and based upon the characteristics of the subsea location to complete a completion installation, intervention, and/or testing activity.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: An apparatus includes an engagement device to be disposed on a landing string. The engagement device includes a retracted state to allow the apparatus to be run inside a riser and an expanded state to engage the riser to secure the apparatus to the riser. The apparatus further includes an actuator assembly to be disposed on the landing string. The actuator assembly is remotely actuatable from a sea surface to rotate a tubing of the landing string relative to the engagement device to rotate the landing string to orient a tubing hanger assembly.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: In-riser power generation devices and methods are utilized to generate power subsea to operate subsea devices of a subsea well system. A turbine power generator is located in fluid communication with a subsea fluid flow path of a subsea well system and the turbine power generator is operationally connected to a subsea power device.

Abstract: A technique facilitates powering of devices at a subsea location without requiring routing of hydraulic pressure and/or electric signals through an umbilical from a surface location. A fluid flow, such as an injection chemical fluid flow, is at least partially routed through a flow converter disposed at a subsea location. The flow converter converts energy from the fluid flow to energy used to operate a power generation device. The power generation device may be designed to generate electrical, hydraulic, or other suitable power which is utilized at the subsea location.

Abstract: A piping system for housing system components for regulating the flow of fluid therethrough is provided. The piping system includes an inner small diameter length of piping through which hot fluids flow, an outer larger diameter length of piping surrounded by cold fluid, and an annulus between the small and larger diameter piping in which the system components are received. Insulation material extends about a predetermined section of the small diameter length of piping for restricting heat transfer therefrom to the system components in the annulus and allowing heat transfer from the system components in the annulus to the outer piping.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Certain chemical entities are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: A technique enables protection of subsea wells. The technique employs a subsea test tree designed to ensure control over the well in a variety of situations. The subsea test tree is formed with at least one shut-off valve to protect against unwanted release of fluids from the subsea test tree. The subsea test tree also is coupled with and controlled by a control system having a subsea control module mounted to an interior mandrel.

Abstract: Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.